<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="editorial"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Viruses</journal-id><journal-id journal-id-type="iso-abbrev">Viruses</journal-id><journal-id journal-id-type="publisher-id">viruses</journal-id><journal-title-group><journal-title>Viruses</journal-title></journal-title-group><issn pub-type="epub">1999-4915</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC11680288</article-id><article-id pub-id-type="doi">10.3390/v16121939</article-id><article-id pub-id-type="publisher-id">viruses-16-01939</article-id><article-categories><subj-group subj-group-type="heading"><subject>Editorial</subject></subj-group></article-categories><title-group><article-title>Exploring the Mechanisms for Virus Invasion at the Barrier of Host Defense Involving Signaling Pathways</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-0083-6129</contrib-id><name><surname>Hahm</surname><given-names>Bumsuk</given-names></name></contrib></contrib-group><aff id="af1-viruses-16-01939">Departments of Surgery &#x00026; Molecular Microbiology and Immunology, University of Missouri, Columbia, MO 65212, USA; <email>hahmb@health.missouri.edu</email></aff><pub-date pub-type="epub"><day>19</day><month>12</month><year>2024</year></pub-date><pub-date pub-type="collection"><month>12</month><year>2024</year></pub-date><volume>16</volume><issue>12</issue><elocation-id>1939</elocation-id><history><date date-type="received"><day>12</day><month>12</month><year>2024</year></date><date date-type="accepted"><day>18</day><month>12</month><year>2024</year></date></history><permissions><copyright-statement>&#x000a9; 2024 by the author.</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><funding-group><award-group><funding-source>NIH/NIAID</funding-source><award-id>R01AI153076</award-id><award-id>R01AI162631</award-id></award-group><funding-statement>The study was supported by NIH/NIAID R01AI153076 and R01AI162631.</funding-statement></funding-group></article-meta></front><body><p>Pathogenic viruses trigger or disrupt multiple signaling networks to establish an environment optimized for their own replication and productive infection. Understanding the core mechanisms of virus&#x02013;host defense interactions and viral pathogenesis could lead to innovative therapeutics for viral diseases. The Special Issue &#x0201c;Viral Strategies to Regulate Host Immunity or Signal Pathways&#x0201d; covered research topics such as virus interaction with the host innate and adaptive immunity and the viral regulation of intracellular signaling pathways.</p><p>In a research article by Zhang et al. [<xref rid="B1-viruses-16-01939" ref-type="bibr">1</xref>], herpes simplex virus type 2 (HSV-2) was shown to use viral UL24 to strongly impair IRF3 phosphorylation and suppress the subsequent synthesis of type I interferons (IFNs). The study further revealed that the N terminal 1&#x02013;202 AA domain of UL24 displayed inhibitory activity that could overcome the activity of IRF-3 or its upstream molecule-induced IFN production. As the type I IFN is the most potent innate immune molecule against virus infections, numerous pathogenic viruses in humans seem to have developed ways to attenuate the IFN response [<xref rid="B2-viruses-16-01939" ref-type="bibr">2</xref>,<xref rid="B3-viruses-16-01939" ref-type="bibr">3</xref>]. As such, extensive research has been performed to identify cellular proteins of the IFN system that can be targeted for designing new host-directed therapies to combat viral infections. The study by Yu et al. [<xref rid="B4-viruses-16-01939" ref-type="bibr">4</xref>] investigated the function of Naringenin, which is a flavonoid found in citrus fruits with diverse pharmacological activities linked to the host innate immunity to porcine reproductive and respiratory syndrome virus (PRRSV) infection. Interestingly, Naringenin enhanced the expression of antiviral cytokines such as type I IFNs and IFN-stimulated genes that were suppressed by PRRSV. The study indicated that Naringenin could activate the RIG-I-MAVS signal pathway. Since PRRSV is known to induce immune suppression, the use of an immune stimulatory agent such as Naringenin may help to prevent the syndrome caused by PPRSV infection. However, any immune regulatory agent needs to be investigated for the possible induction of harmful inflammation and consequent tissue damage. Indeed, the type I IFN response can become pathogenic to the host. The protective- or pathogenic-type I IFN responses have been reviewed in an article written by Jung et al. [<xref rid="B5-viruses-16-01939" ref-type="bibr">5</xref>]. Type I IFNs were first observed to interfere with influenza virus replication by Isaacs and Lindenmann in 1957 [<xref rid="B6-viruses-16-01939" ref-type="bibr">6</xref>], and have been therapeutically used to inhibit multiple viruses and immune-mediated diseases such as multiple sclerosis. However, they could also cause inflammation or support T cell exhaustion in certain chronic viral infections [<xref rid="B7-viruses-16-01939" ref-type="bibr">7</xref>,<xref rid="B8-viruses-16-01939" ref-type="bibr">8</xref>], requiring in-depth interrogation of their mode of action. Type I IFNs have versatile functions that could be affected by factors including the timing of IFN production, type of IFN-responsive cells or pathogens, the stage of immune cell differentiation, etc. Further research in this area remains to be conducted.</p><p>Neutrophils are important innate immune cells that contribute to the clearance of diverse pathogens as well as the induction of inflammatory reactions via the secretion of toxic molecules through granule exocytosis. Lei Hongxing performed transcriptome studies using the blood of patients infected with SARS-CoV-2, from which the most prominent functional category of upregulated genes was identified as neutrophil degranulation and cell cycling [<xref rid="B9-viruses-16-01939" ref-type="bibr">9</xref>]. Further, both physiological and pathological hypoxia can induce the action of genes related to neutrophil degranulation, which further necessitates a comprehensive analysis of the roles of hypoxia [<xref rid="B10-viruses-16-01939" ref-type="bibr">10</xref>] and neutrophil responses during COVID-19.</p><p>Additionally, the role of ferroptosis during viral pathogenesis was reviewed by Huang et al. [<xref rid="B11-viruses-16-01939" ref-type="bibr">11</xref>]. Ferroptosis is a type of cell death caused by intracellular iron metabolism that regulates reactive oxygen species (ROS) and mediates lipid-dependent oxidative damage [<xref rid="B12-viruses-16-01939" ref-type="bibr">12</xref>]. Viruses have often been reported to manipulate cellular ferroptosis to promote viral proliferation. Various steps of viral replication processes or immune evasive mechanisms have been shown to be affected by viral regulation of ferroptosis: examples include regulation of the transport pathway of TfR1 for effective viral entry, increased iron levels for promoting viral enzyme function, and the accumulation of lipid peroxides for viral immune escape.</p><p>In summary, these studies indicate that it is imperative to uncover the mechanisms of virus&#x02013;host interplay and the viral regulation of cellular pathways. A better understanding of the host defense mechanism as well as viral tactics to avoid host immunity should help design advanced therapeutic approaches and improve human health.</p></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The author declares no conflicts of interest.</p></notes><ref-list><title>References</title><ref id="B1-viruses-16-01939"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>B.</given-names></name>
<name><surname>Li</surname><given-names>Y.</given-names></name>
<name><surname>Yang</surname><given-names>P.</given-names></name>
<name><surname>He</surname><given-names>S.</given-names></name>
<name><surname>Li</surname><given-names>W.</given-names></name>
<name><surname>Li</surname><given-names>M.</given-names></name>
<name><surname>Hu</surname><given-names>Q.</given-names></name>
<name><surname>Zhang</surname><given-names>M.</given-names></name>
</person-group><article-title>Herpes Simplex Virus Type 2 Blocks IFN-beta Production through the Viral UL24 N-Terminal Domain-Mediated Inhibition of IRF-3 Phosphorylation</article-title><source>Viruses</source><year>2024</year><volume>16</volume><elocation-id>1601</elocation-id><pub-id pub-id-type="doi">10.3390/v16101601</pub-id><pub-id pub-id-type="pmid">39459934</pub-id>
</element-citation></ref><ref id="B2-viruses-16-01939"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhu</surname><given-names>J.</given-names></name>
<name><surname>Chiang</surname><given-names>C.</given-names></name>
<name><surname>Gack</surname><given-names>M.U.</given-names></name>
</person-group><article-title>Viral evasion of the interferon response at a glance</article-title><source>J. Cell Sci.</source><year>2023</year><volume>136</volume><fpage>260682</fpage><pub-id pub-id-type="doi">10.1242/jcs.260682</pub-id></element-citation></ref><ref id="B3-viruses-16-01939"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Garcia-Sastre</surname><given-names>A.</given-names></name>
<name><surname>Biron</surname><given-names>C.A.</given-names></name>
</person-group><article-title>Type 1 interferons and the virus-host relationship: A lesson in detente</article-title><source>Science</source><year>2006</year><volume>312</volume><fpage>879</fpage><lpage>882</lpage><pub-id pub-id-type="doi">10.1126/science.1125676</pub-id><pub-id pub-id-type="pmid">16690858</pub-id>
</element-citation></ref><ref id="B4-viruses-16-01939"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yu</surname><given-names>J.</given-names></name>
<name><surname>Shi</surname><given-names>H.</given-names></name>
<name><surname>Song</surname><given-names>K.</given-names></name>
<name><surname>Yang</surname><given-names>Y.</given-names></name>
<name><surname>Li</surname><given-names>X.</given-names></name>
<name><surname>Peng</surname><given-names>L.</given-names></name>
<name><surname>Fu</surname><given-names>B.</given-names></name>
<name><surname>Yi</surname><given-names>P.</given-names></name>
</person-group><article-title>Naringenin Improves Innate Immune Suppression after PRRSV Infection by Reactivating the RIG-I-MAVS Signaling Pathway, Promoting the Production of IFN-I</article-title><source>Viruses</source><year>2023</year><volume>15</volume><elocation-id>2172</elocation-id><pub-id pub-id-type="doi">10.3390/v15112172</pub-id><pub-id pub-id-type="pmid">38005850</pub-id>
</element-citation></ref><ref id="B5-viruses-16-01939"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jung</surname><given-names>K.I.</given-names></name>
<name><surname>McKenna</surname><given-names>S.</given-names></name>
<name><surname>Vijayamahantesh</surname><given-names>V.</given-names></name>
<name><surname>He</surname><given-names>Y.</given-names></name>
<name><surname>Hahm</surname><given-names>B.</given-names></name>
</person-group><article-title>Protective versus Pathogenic Type I Interferon Responses during Virus Infections</article-title><source>Viruses</source><year>2023</year><volume>15</volume><elocation-id>1916</elocation-id><pub-id pub-id-type="doi">10.3390/v15091916</pub-id><pub-id pub-id-type="pmid">37766322</pub-id>
</element-citation></ref><ref id="B6-viruses-16-01939"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Isaacs</surname><given-names>A.</given-names></name>
<name><surname>Lindenmann</surname><given-names>J.</given-names></name>
</person-group><article-title>Virus interference. I. The interferon. By A. Isaacs and J. Lindenmann, 1957</article-title><source>J. Interferon. Res.</source><year>1987</year><volume>7</volume><fpage>429</fpage><lpage>438</lpage><pub-id pub-id-type="doi">10.1089/jir.1987.7.429</pub-id></element-citation></ref><ref id="B7-viruses-16-01939"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Teijaro</surname><given-names>J.R.</given-names></name>
<name><surname>Ng</surname><given-names>C.</given-names></name>
<name><surname>Lee</surname><given-names>A.M.</given-names></name>
<name><surname>Sullivan</surname><given-names>B.M.</given-names></name>
<name><surname>Sheehan</surname><given-names>K.C.</given-names></name>
<name><surname>Welch</surname><given-names>M.</given-names></name>
<name><surname>Schreiber</surname><given-names>R.D.</given-names></name>
<name><surname>de la Torre</surname><given-names>J.C.</given-names></name>
<name><surname>Oldstone</surname><given-names>M.B.</given-names></name>
</person-group><article-title>Persistent LCMV infection is controlled by blockade of type I interferon signaling</article-title><source>Science</source><year>2013</year><volume>340</volume><fpage>207</fpage><lpage>211</lpage><pub-id pub-id-type="doi">10.1126/science.1235214</pub-id><pub-id pub-id-type="pmid">23580529</pub-id>
</element-citation></ref><ref id="B8-viruses-16-01939"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wilson</surname><given-names>E.B.</given-names></name>
<name><surname>Yamada</surname><given-names>D.H.</given-names></name>
<name><surname>Elsaesser</surname><given-names>H.</given-names></name>
<name><surname>Herskovitz</surname><given-names>J.</given-names></name>
<name><surname>Deng</surname><given-names>J.</given-names></name>
<name><surname>Cheng</surname><given-names>G.</given-names></name>
<name><surname>Aronow</surname><given-names>B.J.</given-names></name>
<name><surname>Karp</surname><given-names>C.L.</given-names></name>
<name><surname>Brooks</surname><given-names>D.G.</given-names></name>
</person-group><article-title>Blockade of chronic type I interferon signaling to control persistent LCMV infection</article-title><source>Science</source><year>2013</year><volume>340</volume><fpage>202</fpage><lpage>207</lpage><pub-id pub-id-type="doi">10.1126/science.1235208</pub-id><pub-id pub-id-type="pmid">23580528</pub-id>
</element-citation></ref><ref id="B9-viruses-16-01939"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lei</surname><given-names>H.</given-names></name>
</person-group><article-title>Hypoxia and Activation of Neutrophil Degranulation-Related Genes in the Peripheral Blood of COVID-19 Patients</article-title><source>Viruses</source><year>2024</year><volume>16</volume><elocation-id>201</elocation-id><pub-id pub-id-type="doi">10.3390/v16020201</pub-id><pub-id pub-id-type="pmid">38399976</pub-id>
</element-citation></ref><ref id="B10-viruses-16-01939"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Serebrovska</surname><given-names>Z.O.</given-names></name>
<name><surname>Chong</surname><given-names>E.Y.</given-names></name>
<name><surname>Serebrovska</surname><given-names>T.V.</given-names></name>
<name><surname>Tumanovska</surname><given-names>L.V.</given-names></name>
<name><surname>Xi</surname><given-names>L.</given-names></name>
</person-group><article-title>Hypoxia, HIF-1alpha, and COVID-19: From pathogenic factors to potential therapeutic targets</article-title><source>Acta Pharmacol. Sin.</source><year>2020</year><volume>41</volume><fpage>1539</fpage><lpage>1546</lpage><pub-id pub-id-type="doi">10.1038/s41401-020-00554-8</pub-id><pub-id pub-id-type="pmid">33110240</pub-id>
</element-citation></ref><ref id="B11-viruses-16-01939"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Huang</surname><given-names>R.</given-names></name>
<name><surname>Wu</surname><given-names>J.</given-names></name>
<name><surname>Ma</surname><given-names>Y.</given-names></name>
<name><surname>Kang</surname><given-names>K.</given-names></name>
</person-group><article-title>Molecular Mechanisms of Ferroptosis and Its Role in Viral Pathogenesis</article-title><source>Viruses</source><year>2023</year><volume>15</volume><elocation-id>2373</elocation-id><pub-id pub-id-type="doi">10.3390/v15122373</pub-id><pub-id pub-id-type="pmid">38140616</pub-id>
</element-citation></ref><ref id="B12-viruses-16-01939"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dixon</surname><given-names>S.J.</given-names></name>
<name><surname>Lemberg</surname><given-names>K.M.</given-names></name>
<name><surname>Lamprecht</surname><given-names>M.R.</given-names></name>
<name><surname>Skouta</surname><given-names>R.</given-names></name>
<name><surname>Zaitsev</surname><given-names>E.M.</given-names></name>
<name><surname>Gleason</surname><given-names>C.E.</given-names></name>
<name><surname>Patel</surname><given-names>D.N.</given-names></name>
<name><surname>Bauer</surname><given-names>A.J.</given-names></name>
<name><surname>Cantley</surname><given-names>A.M.</given-names></name>
<name><surname>Yang</surname><given-names>W.S.</given-names></name>
<etal/>
</person-group><article-title>Ferroptosis: An iron-dependent form of nonapoptotic cell death</article-title><source>Cell</source><year>2012</year><volume>149</volume><fpage>1060</fpage><lpage>1072</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2012.03.042</pub-id><pub-id pub-id-type="pmid">22632970</pub-id>
</element-citation></ref></ref-list></back></article>